AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Company profile
Ticker
DOMH
Exchange
Website
CEO
Anthony Hayes
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aikido Pharma Inc., AIkido Pharma Inc., BIOSPHERICS INC, SPHERIX INC
SEC CIK
Corporate docs
Subsidiaries
AIkido Labs LLC ...
IRS number
520849320
DOMH stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Dec 22
8-K
Submission of Matters to a Vote of Security Holders
6 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Entry into a Material Definitive Agreement
21 Oct 22
DEFA14A
Additional proxy soliciting materials
21 Oct 22
DEF 14A
Definitive proxy
21 Oct 22
8-K
Other Events
7 Oct 22
8-K
Entry into a Material Definitive Agreement
29 Sep 22
8-K
Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer
9 Sep 22
Latest ownership filings
3
Christopher Franklin Devall
6 Jan 23
SC 13D
Wool Kyle Michael
28 Dec 22
4
Kyle Michael Wool
22 Dec 22
4
Kyle Michael Wool
21 Dec 22
4
Kyle Michael Wool
20 Dec 22
4
Kyle Michael Wool
19 Dec 22
4
Anthony Hayes
16 Dec 22
4
Kyle Michael Wool
16 Dec 22
4
Anthony Hayes
15 Dec 22
4
Kyle Michael Wool
15 Dec 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 34.50 mm | 34.50 mm | 34.50 mm | 34.50 mm | 34.50 mm | 34.50 mm |
| Cash burn (monthly) | 1.43 mm | (no burn) | 1.70 mm | 1.15 mm | 954.33 k | 898.58 k |
| Cash used (since last report) | 8.27 mm | n/a | 9.83 mm | 6.64 mm | 5.51 mm | 5.19 mm |
| Cash remaining | 26.22 mm | n/a | 24.67 mm | 27.86 mm | 28.98 mm | 29.30 mm |
| Runway (months of cash) | 18.3 | n/a | 14.5 | 24.2 | 30.4 | 32.6 |
Institutional ownership, Q3 2022
13.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 7 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 4.68 mm |
| Total shares | 724.60 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 193.54 k | $1.32 mm |
| Intracoastal Capital | 159.81 k | $815.00 k |
| Two Sigma Advisers | 86.70 k | $593.00 k |
| BLK Blackrock | 75.28 k | $515.00 k |
| Dimensional Fund Advisors | 57.85 k | $396.00 k |
| Two Sigma Investments | 53.60 k | $367.00 k |
| Geode Capital Management | 43.41 k | $296.00 k |
| Renaissance Technologies | 32.93 k | $225.00 k |
| Equitec Proprietary Markets | 18.80 k | $129.00 k |
| Tower Research Capital | 1.84 k | $12.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Dec 22 | Kyle Michael Wool | Common Stock | Buy | Acquire P | No | No | 3.588 | 6,000 | 21.53 k | 272,792 |
| 19 Dec 22 | Kyle Michael Wool | Common Stock | Buy | Acquire P | No | No | 3.593 | 5,000 | 17.97 k | 266,792 |
| 16 Dec 22 | Kyle Michael Wool | Common Stock | Buy | Acquire P | No | No | 3.705 | 5,000 | 18.53 k | 261,792 |
| 15 Dec 22 | Kyle Michael Wool | Common Stock | Buy | Acquire P | No | No | 3.687 | 5,000 | 18.44 k | 280,322 |
Press releases
Dominari Financial Granted Approval to Acquire Broker Dealer
21 Mar 23
Dominari Holdings Provides Update on Share Repurchase Program
17 Mar 23
Dominari Holdings Provides Business Update
14 Mar 23
Dominari Holdings Provides Update on Share Repurchase Program
10 Mar 23
Dominari Holdings Provides Update on Share Repurchase Program
6 Mar 23